Beamion LUNG-1：進行癌（HER2遺伝子変異を有する固形癌）の患者を対象に、ゾンゲルチニブの異なる用量を試験する研究

基本情報

NCT ID

NCT04886804

ステータス

募集中

試験のフェーズ

第1相

試験タイプ

介入

目標被験者数

554

治験依頼者名

Boehringer Ingelheim

概要

The study has 2 parts. The first part is open to adults with different types of advanced cancer (solid tumours with changes in the HER2 gene) for whom previous treatment was not successful. The second part is open to people with non-small cell lung cancer with a specific mutation in the HER2 gene. The purpose of the first study part is to find the highest dose of a medicine called zongertinib the participants can tolerate. Once this dose is found, it will be used in the second study part to test whether zongertinib can make tumours shrink. In this study, zongertinib is given to people for the first time. Participants take zongertinib as tablets once a day or twice a day. The participants are in the study for as long as they benefit from and can tolerate treatment. Study doctors regularly check the participants' health and monitor the tumours. The doctors also take note of any unwanted effects that could have been caused by zongertinib.

対象疾患

介入

依頼者（Sponsor）

実施施設 (7)